ABC transporters in lung cancer clinical outcome: a systematic review and integrative analysis

Haodong Tian

doi:10.54254/3049-5458/2026.32736

Article Information

Received: 1 January 0001

Published: 8 April 2026

DOI: https://doi.org/10.54254/3049-5458/2026.32736

Article Type: Research Article

Cite this article

Tian,H. (2026). ABC transporters in lung cancer clinical outcome: a systematic review and integrative analysis. Journal of Clinical Technology and Theory,4(2),111-133.

Data availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

Disclaimer/Publisher's Note

The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

About this Journal

Journal: Journal of Clinical Technology and Theory

Volume: Vol.4, Issue 2

ISSN: 3049-5458 (Print) / 3049-5466 (Online)

Copyright & License

[1]Zhou, J., Xu, Y., Liu, J., Feng, L., Yu, J., & Chen, D. (2024). Global burden of lung cancer in 2022 and projections to 2050: Incidence and mortality estimates from GLOBOCAN.Cancer Epidemiology,93, 102693. https: //doi.org/10.1016/j.canep.2024.102693

[2]Zhang, Y., Luo, G., Etxeberria, J., & Hao, Y. (2021). Global patterns and trends in lung cancer incidence: A population-based study.Journal of Thoracic Oncology,16(6), 933–944. https: //doi.org/10.1016/j.jtho.2021.01.1626

[3]Surveillance, Epidemiology, and End Results (SEER) Program. (n.d.)(2026). Cancer of the lung and bronchus – cancer stat facts. National Cancer Institute.Retrieved January,13, from https: //seer.cancer.gov/statfacts/html/lungb.html

[4]Wangari-Talbot, J., & Hopper-Borge, E. (2013). Drug resistance mechanisms in non-small cell lung carcinoma.Journal of Cancer Research Updates,2(4), 265–282. https: //doi.org/10.6000/1929-2279.2013.02.04.5

[5]Ashrafi, A., Akter, Z., Modareszadeh, P., Modareszadeh, P., Berisha, E., Alemi, P. S., Chacon Castro, M. d. C., Deese, A. R., & Zhang, L. (2022). Current landscape of therapeutic resistance in lung cancer and promising strategies to overcome resistance.Cancers,14(19), 4562. https: //doi.org/10.3390/cancers14194562

[6]Papadaki, C., Mavroudis, D., Trypaki, M., Koutsopoulos, A., Stathopous, E., Hatzidaki, D., Tsakalaki, E., Georgoulias, V., & Souglakos, J. (2009). Tumoral expression of TXR1 and TSP1 predicts overall survival of patients with lung adenocarcinoma treated with first-line docetaxel-gemcitabine regimen.Clinical Cancer Research,15(11), 3827–3833. https: //doi.org/10.1158/1078-0432.CCR-08-3027

[7]Yeh, J., Hsu, W., Wang, J., Ho, S., & Kao, A. (2003). Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer with P-glycoprotein expression.Respiration,70(1), 32–35. https: //doi.org/10.1159/000068411

[8]Wang, X., Zheng, K., & Hao, Z. (2024). In-depth analysis of immune cell landscapes reveals differences between lung adenocarcinoma and lung squamous cell carcinoma.Frontiers in Oncology,14, 1338634. https: //doi.org/10.3389/fonc.2024.1338634

[9]Shen, Y., Chen, J.-Q., & Li, X.-P. (2025). Differences between lung adenocarcinoma and lung squamous cell carcinoma: Driver genes, therapeutic targets, and clinical efficacy.Genes & Diseases,12(3), 101374. https: //doi.org/10.1016/j.gendis.2024.101374

[10]Gottesman, M. M., Fojo, T., & Bates, S. E. (2002). Multidrug resistance in cancer: Role of ATP–dependent transporters.Nature Reviews Cancer,2(1), 48–58. https: //doi.org/10.1038/nrc706

[11]Zou, F., Seike, M., Noro, R., Kunugi, S., Kubota, K., & Gemma, A. (2017). Prognostic significance of ABCB1 in stage I lung adenocarcinoma.Oncology Letters,14(1), 313–321. https: //doi.org/10.3892/ol.2017.6145

[12]Omori, M., Noro, R., Seike, M., Matsuda, K., Hirao, M., Fukuizumi, A., Takano, N., Miyanaga, A., & Gemma, A. (2022). Inhibitors of ABCB1 and ABCG2 overcame resistance to topoisomerase inhibitors in small cell lung cancer.Thoracic Cancer,13(15), 2142–2151. https: //doi.org/10.1111/1759-7714.14527

[13]Wang, T., Rao, D., Fu, C., Luo, Y., Lu, J., Liang, H., Xia, L., & Huang, W. (2024). Pan-cancer analysis of ABCC1 as a potential prognostic and immunological biomarker.Translational Oncology,41, 101882. https: //doi.org/10.1016/j.tranon.2024.101882

[14]Choi, C.-H. (2005). ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal.Cancer Cell International,5, 30. https: //doi.org/10.1186/1475-2867-5-30

[15]Bendayan, R., Ronaldson, P. T., Gingras, D., & Bendayan, M. (2006). In situ localization of P-glycoprotein (ABCB1) in human and rat brain.Journal of Histochemistry & Cytochemistry,54(10), 1159–1167. https: //doi.org/10.1369/jhc.5A6870.2006

[16]Cascorbi, I. (2011). P-glycoprotein: Tissue distribution, substrates, and functional consequences of genetic variations. In M. F. Fromm & R. B. Kim (Eds.), Drug transporters(pp. 261–283).Springer. https: //doi.org/10.1007/978-3-642-14541-4_6

[17]Nunoya, K., Grant, C. E., Zhang, D., Cole, S. P. C., & Deeley, R. G. (2003). Molecular cloning and pharmacological characterization of rat multidrug resistance protein 1 (MRP1).Drug Metabolism and Disposition,31(8), 1016–1026. https: //doi.org/10.1124/dmd.31.8.1016

[18]Salagacka-Kubiak, A., Zawada, D., Saed, L., Kordek, R., Jelen, A., & Balcerczak, E. (2023). ABCG2 gene and ABCG2 protein expression in colorectal cancer—in silico and wet analysis.International Journal of Molecular Sciences,24(13), 10539. https: //doi.org/10.3390/ijms241310539

[19]Oguri, T., Achiwa, H., Sato, S., Bessho, Y., Takano, Y., Miyazaki, M., Muramatsu, H., Maeda, H., Niimi, T., & Ueda, R. (2006). The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small cell lung cancer: A role of ABCC5 in gemcitabine sensitivity.Molecular Cancer Therapeutics,5(7), 1800–1806. https: //doi.org/10.1158/1535-7163.MCT-06-0025

[20]Pan, Y., Wu, M., & Cai, H. (2024). Role of ABCC5 in cancer drug resistance and its potential as a therapeutic target.Frontiers in Cell and Developmental Biology,12, 1446418. https: //doi.org/10.3389/fcell.2024.1446418

[21]Fletcher, J. I., Haber, M., Henderson, M. J., & Norris, M. D. (2010). ABC transporters in cancer: More than just drug efflux pumps.Nature Reviews Cancer,10(2), 147–156. https: //doi.org/10.1038/nrc2789

[22]Duvivier, L., Gerard, L., Diaz, A., & Gillet, J.-P. (2024). Linking ABC transporters to the hallmarks of cancer.Trends in Cancer,10(2), 124–134. https: //doi.org/10.1016/j.trecan.2023.09.013

[23]Berger, W., Setinek, U., Hollaus, P., Zidek, T., Steiner, E., Elbling, L., Cantonati, H., Attems, J., Gsur, A., & Micksche, M. (2005). Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: Prognostic implications.Journal of Cancer Research and Clinical Oncology,131(6), 355–363. https: //doi.org/10.1007/s00432-004-0653-9

[24]Zhao, X., Guo, Y., Yue, W., Zhang, L., Gu, M., & Wang, Y. (2014). ABCC4 is required for cell proliferation and tumorigenesis in non-small cell lung cancer.OncoTargets and Therapy,7, 343–351. https: //doi.org/10.2147/OTT.S56029

[25]Yoh, K., Ishii, G., Yokose, T., Minegishi, Y., Tsuta, K., Goto, K., Nishiwaki, Y., Kodama, T., Suga, M., & Ochiai, A. (2004). Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer.Clinical Cancer Research,10(5), 1691–1697. https: //doi.org/10.1158/1078-0432.CCR-0937-3

[26]Li, X.-Q., Li, J., Shi, S.-B., Chen, P., Yu, L.-C., & Bao, Q.-L. (2009). Expression of MRP1, BCRP, LRP and ERCC1 as prognostic factors in non-small cell lung cancer patients receiving postoperative cisplatin-based chemotherapy.The International Journal of Biological Markers,24(4), 230–237. https: //doi.org/10.1177/172460080902400403

[27]Zhao, Y., Lu, H., Yan, A., Yang, Y., Meng, Q., Sun, L., Pang, H., Li, C., Dong, X., & Cai, L. (2013). ABCC3 as a marker for multidrug resistance in non-small cell lung cancer.Scientific Reports,3(1), 3120. https: //doi.org/10.1038/srep03120

[28]Uemura, T., Oguri, T., Ozasa, H., Takakuwa, O., Miyazaki, M., Maeno, K., Sato, S., & Ueda, R. (2010). ABCC11/MRP8 confers pemetrexed resistance in lung cancer.Cancer Science,101(11), 2404–2410. https: //doi.org/10.1111/j.1349-7006.2010.01690.x

[29]Song, M., Gao, L., Zang, J., & Xing, X. (2023). ABCA3, a tumor suppressor gene, inhibits the proliferation, migration and invasion of lung adenocarcinoma by regulating the epithelial-mesenchymal transition process.Oncology Letters,26(4), 433. https: //doi.org/10.3892/ol.2023.14006

[30]Mack, J. T., Beljanski, V., Tew, K. D., & Townsend, D. M. (2006). The ATP-binding cassette transporter ABCA2 as a mediator of intracellular trafficking.Biomedicine & Pharmacotherapy,60(9), 587–592. https: //doi.org/10.1016/j.biopha.2006.07.090

[31]Boonstra, R., Timmer-Bosscha, H., van Echten-Arends, J., van der Kolk, D., van den Berg, A., de Jong, B., Tew, K., Poppema, S., & de Vries, E. (2004). Mitoxantrone resistance in a small cell lung cancer cell line is associated with ABCA2 upregulation.British Journal of Cancer,90(12), 2411–2417. https: //doi.org/10.1038/sj.bjc.6601863

[32]Mack, J. T., Helke, K. L., Normand, G., Green, C., Townsend, D. M., & Tew, K. D. (2011). ABCA2 transporter deficiency reduces incidence of TRAMP prostate tumor metastasis and cellular chemotactic migration.Cancer Letters,300(2), 154–161. https: //doi.org/10.1016/j.canlet.2010.09.017

[33]Wittmann, T., Schindlbeck, U., Höppner, S., Kinting, S., Frixel, S., Kröner, C., Liebisch, G., Hegermann, J., Aslanidis, C., Brasch, F., Reu, S., Lasch, P., Zarbock, R., & Griese, M. (2016). Tools to explore ABCA3 mutations causing interstitial lung disease.Pediatric Pulmonology,51(12), 1284–1294. https: //doi.org/10.1002/ppul.23471

[34]Klugbauer, N., & Hofmann, F. (1996). Primary structure of a novel ABC transporter with a chromosomal localization on the band encoding the multidrug resistance-associated protein.FEBS Letters,391(1–2), 61–65. https: //doi.org/10.1016/0014-5793(96)00700-4

[35]Wang, J.-Q., Wu, Z.-X., Yang, Y., Teng, Q.-X., Li, Y.-D., Lei, Z.-N., Jani, K. A., Kaushal, N., & Chen, Z.-S. (2021). ATP-binding cassette (ABC) transporters in cancer: A review of recent updates.Journal of Evidence-Based Medicine,14(3), 232–256. https: //doi.org/10.1111/jebm.12434

[36]Beers, M. F., & Mulugeta, S. (2017). The biology of the ABCA3 lipid transporter in lung health and disease.Cell and Tissue Research,367(3), 481–493. https: //doi.org/10.1007/s00441-016-2554-z

[37]Steinbach, D., Gillet, J.-P., Sauerbrey, A., Gruhn, B., Dawczynski, K., Bertholet, V., de Longueville, F., Zintl, F., Remacle, J., & Efferth, T. (2006). ABCA3 as a possible cause of drug resistance in childhood acute myeloid leukemia.Clinical Cancer Research,12(14), 4357–4363. https: //doi.org/10.1158/1078-0432.CCR-05-2587

[38]Overbeck, T. R., Hupfeld, T., Krause, D., Waldmann-Beushausen, R., Chapuy, B., Guedenzoph, B., Aung, T., Inagaki, N., Schoendube, F. A., Danner, B. C., Truemper, L., & Wulf, G. G. (2013). Intracellular ATP-binding cassette transporter A3 is expressed in lung cancer cells and modulates susceptibility to cisplatin and paclitaxel.Oncology,84(6), 362–370. https: //doi.org/10.1159/000348884

[39]Overbeck, T. R., Arnemann, J., Waldmann-Beushausen, R., Truemper, L., Schoendube, F. A., Reuter-Jessen, K., & Danner, B. C. (2017). ABCA3 phenotype in non-small cell lung cancer indicates poor outcome.Oncology,93(4), 270–278. https: //doi.org/10.1159/000477619

[40]Takakuwa, O., Oguri, T., Ozasa, H., Uemura, T., Kasai, D., Miyazaki, M., Maeno, K., & Sato, S. (2011). Over-expression of MDR1 in amrubicinol-resistant lung cancer cells.Cancer Chemotherapy and Pharmacology,68(3), 669–676. https: //doi.org/10.1007/s00280-010-1533-4

[41]Dallas, S., Ronaldson, P. T., Bendayan, M., & Bendayan, R. (2004). Multidrug resistance protein 1-mediated transport of saquinavir by microglia.NeuroReport,15(7), 1183–1186. https: //doi.org/10.1097/00001756-200405190-00020

[42]Zheng, Y., Ma, L., & Sun, Q. (2021). Clinically-relevant ABC transporter for anti-cancer drug resistance.Frontiers in Pharmacology,12, 648407. https: //doi.org/10.3389/fphar.2021.648407

[43]Cui, Y., König, J., Buchholz, U., Spring, H., Leier, I., & Keppler, D. (1999). Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells.Molecular Pharmacology,55(5), 929–937. https: //doi.org/10.1016/S0026-895X(24)23190-4

[44]Büchler, M., König, J., Brom, M., Kartenbeck, J., Spring, H., Horie, T., & Keppler, D. (1996). cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats.Journal of Biological Chemistry,271(25), 15091–15098. https: //doi.org/10.1074/jbc.271.25.15091

[45]Wang, Y., Gan, X., Cheng, X., Jia, Y., Wang, G., Tang, X., Du, H., Li, X., Liu, X., Xing, X., Ji, J., & Li, Z. (2024). ABCC2 induces metabolic vulnerability and cellular ferroptosis via enhanced glutathione efflux in gastric cancer.Clinical and Translational Medicine,14(8), e1754. https: //doi.org/10.1002/ctm2.1754

[46]Castillo, V. F., Zakhary, A., Rotondo, F., Di Ciano-Oliveira, C., Hamdani, M., Adona, E., van der Kwast, T., Trpkov, K., & Saleeb, R. (2025). Papillary renal cell carcinoma with high-ABCC2 shows an immune-evasive profile associated with favorable response to immunotherapy.The Journal of Pathology. Advance online publication. https: //doi.org/10.1002/path.70001

[47]Zelcer, N., Saeki, T., Reid, G., Beijnen, J. H., & Borst, P. (2001). Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3).Journal of Biological Chemistry,276(49), 46400–46407. https: //doi.org/10.1074/jbc.M107041200

[48]Liu, X., Yao, D., Liu, C., Cao, Y., Yang, Q., Sun, Z., & Liu, D. (2016). Overexpression of ABCC3 promotes cell proliferation, drug resistance, and aerobic glycolysis and is associated with poor prognosis in urinary bladder cancer patients.Tumor Biology,37(6), 8367–8374. https: //doi.org/10.1007/s13277-015-4703-5

[49]Miah, M. F., Conseil, G., & Cole, S. P. C. (2016). N-linked glycans do not affect plasma membrane localization of multidrug resistance protein 4 (MRP4) but selectively alter its prostaglandin E2 transport activity.Biochemical and Biophysical Research Communications,469(4), 954–959. https: //doi.org/10.1016/j.bbrc.2015.12.095

[50]Gancedo, S. N., Sahores, A., Gómez, N., Di Siervi, N., May, M., Yaneff, A., de Sousa Serro, M. G., Fraunhoffer, N., Dusetti, N., Iovanna, J., Shayo, C., Davio, C. A., & González, B. (2024). The xenobiotic transporter ABCC4/MRP4 promotes epithelial mesenchymal transition in pancreatic cancer.Frontiers in Pharmacology,15, 1432851. https: //doi.org/10.3389/fphar.2024.1432851

[51]Jansen, R. S., Mahakena, S., de Haas, M., Borst, P., & van de Wetering, K. (2015). ATP-binding cassette subfamily C member 5 (ABCC5) functions as an efflux transporter of glutamate conjugates and analogs.Journal of Biological Chemistry,290(51), 30429–30440. https: //doi.org/10.1074/jbc.M115.692103

[52]Hallows, K. R., Kobinger, G. P., Wilson, J. M., Witters, L. A., & Foskett, J. K. (2003). Physiological modulation of CFTR activity by AMP-activated protein kinase in polarized T84 cells.American Journal of Physiology-Cell Physiology,284(5), C1297–C1308. https: //doi.org/10.1152/ajpcell.00227.2002

[53]Aleksandrov, A. A., Aleksandrov, L. A., & Riordan, J. R. (2007). CFTR (ABCC7) is a hydrolyzable-ligand-gated channel.Pflügers Archiv - European Journal of Physiology,453(5), 693–702. https: //doi.org/10.1007/s00424-006-0140-z

[54]Xiao, Q., Koutsilieri, S., Sismanoglou, D.-C., & Lauschke, V. M. (2022). CFTR reduces the proliferation of lung adenocarcinoma and is a strong predictor of survival in both smokers and non-smokers.Journal of Cancer Research and Clinical Oncology,148(12), 3293–3302. https: //doi.org/10.1007/s00432-022-04106-x

[55]Zhang, J., Wang, Y., Jiang, X., & Chan, H. C. (2018). Cystic fibrosis transmembrane conductance regulator—emerging regulator of cancer.Cellular and Molecular Life Sciences,75(10), 1737–1756. https: //doi.org/10.1007/s00018-018-2755-6

[56]Chen, Z.-S., Guo, Y., Belinsky, M. G., Kotova, E., & Kruh, G. D. (2005). Transport of bile acids, sulfated steroids, estradiol 17-β-d-glucuronide, and leukotriene C4 by human multidrug resistance protein 8 (ABCC11).Molecular Pharmacology,67(2), 545–557. https: //doi.org/10.1124/mol.104.007138

[57]Bortfeld, M., Rius, M., König, J., Herold-Mende, C., Nies, A. T., & Keppler, D. (2006). Human multidrug resistance protein 8 (MRP8/ABCC11), an apical efflux pump for steroid sulfates, is an axonal protein of the CNS and peripheral nervous system.Neuroscience,137(4), 1247–1257. https: //doi.org/10.1016/j.neuroscience.2005.10.025

[58]Arlanov, R., Lang, T., Jedlitschky, G., Schaeffeler, E., Ishikawa, T., Schwab, M., & Nies, A. T. (2016). Functional characterization of common protein variants in the efflux transporter ABCC11 and identification of T546M as functionally damaging variant.The Pharmacogenomics Journal,16(2), 193–201. https: //doi.org/10.1038/tpj.2015.27

[59]Funazo, T., Tsuji, T., Ozasa, H., Furugaki, K., Yoshimura, Y., Oguri, T., Ajimizu, H., Yasuda, Y., Nomizo, T., Sakamori, Y., Yoshida, H., Kim, Y. H., & Hirai, T. (2020). Acquired resistance to alectinib in ALK-rearranged lung cancer due to ABCC11/MRP8 overexpression in a clinically paired resistance model.Molecular Cancer Therapeutics,19(6), 1320–1327. https: //doi.org/10.1158/1535-7163.MCT-19-0649

[60]Yamada, Y., Yoshimatsu, K., Yokomizo, H., Okayama, S., & Shiozawa, S. (2020). Expression of ATP-binding cassette transporter 11 (ABCC11) protein in colon cancer.Anticancer Research,40(10), 5405–5409. https: //doi.org/10.21873/anticanres.14549

[61]Mao, Q., & Unadkat, J. D. (2015). Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport—an update.The AAPS Journal,17(1), 65–82. https: //doi.org/10.1208/s12248-014-9668-6

[62]Yang, A., Alrosan, A. Z., Sharpe, L. J., Brown, A. J., Callaghan, R., & Gelissen, I. C. (2021). Regulation of ABCG4 transporter expression by sterols and LXR ligands.Biochimica et Biophysica Acta (BBA) - General Subjects,1865(1), 129769. https: //doi.org/10.1016/j.bbagen.2020.129769

[63]Oldfield, S., Lowry, C. A., Ruddick, J., & Lightman, S. L. (2002). ABCG4: A novel human white family ABC-transporter expressed in the brain and eye.Biochimica et Biophysica Acta (BBA) - Molecular Cell Research,1591(1), 175–179. https: //doi.org/10.1016/S0167-4889(02)00269-0

[64]Yang, G., Wang, X.-J., Huang, L.-J., Zhou, Y.-A., Tian, F., Zhao, J.-B., Chen, P., Liu, B.-Y., Wen, M.-M., Li, X.-F., & Zhang, Z.-P. (2015). High ABCG4 expression is associated with poor prognosis in non-small-cell lung cancer patients treated with cisplatin-based chemotherapy.PLOS ONE, 10(8), e0135576. https: //doi.org/10.1371/journal.pone.0135576

[65]Mallappa, S., Neeli, P. K., Karnewar, S., & Kotamraju, S. (2019). Doxorubicin induces prostate cancer drug resistance by upregulation of ABCG4 through GSH depletion and CREB activation: Relevance of statins in chemosensitization.Molecular Carcinogenesis,58(7), 1118–1133. https: //doi.org/10.1002/mc.22996

[66]Rijavec, M., Silar, M., Triller, N., Kern, I., Cegovnik, U., Kosnik, M., & Korosec, P. (2011). Expressions of topoisomerase IIα and BCRP in metastatic cells are associated with overall survival in small cell lung cancer patients.Pathology & Oncology Research,17(3), 691–696. https: //doi.org/10.1007/s12253-011-9370-2

[67]Chiou, J. F., Liang, J. A., Hsu, W. H., Wang, J. J., Ho, S. T., & Kao, A. (2003). Comparing the relationship of Taxol-based chemotherapy response with P-glycoprotein and lung resistance-related protein expression in non-small cell lung cancer.Lung,181(5), 267–273. https: //doi.org/10.1007/s00408-003-1029-7

[68]Triller, N., Korosec, P., Kern, I., Kosnik, M., & Debeljak, A. (2006). Multidrug resistance in small cell lung cancer: Expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease.Lung Cancer,54(2), 235–240. https: //doi.org/10.1016/j.lungcan.2006.06.019

[69]Yeh, J., Hsu, N., Hsu, W., Tsai, C., Lin, C., & Liang, J. (2005). Comparison of chemotherapy response with P-glycoprotein, multidrug resistance-related protein-1, and lung resistance-related protein expression in untreated small cell lung cancer.Lung,183(3), 177–183. https: //doi.org/10.1007/s00408-004-2532-1

[70]Li, J., Li, Z.-N., Yu, L.-C., Bao, Q.-L., Wu, J.-R., Shi, S.-B., & Li, X.-Q. (2010). Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non-small cell lung cancer who received neoadjuvant chemotherapy.Lung Cancer,69(1), 116–122. https: //doi.org/10.1016/j.lungcan.2009.09.013

[71]Fang, L., Sheng, H., Wan, D., Zhu, C., Jiang, R., Sun, X., & Feng, J. (2018). Prognostic role of multidrug resistance-associated protein 1 expression and platelet count in operable non-small cell lung cancer.Oncology Letters,16(1), 1123–1132. https: //doi.org/10.3892/ol.2018.8763

[72]Ota, S., Ishii, G., Goto, K., Kubota, K., Kim, Y. H., Kojika, M., Murata, Y., Yamazaki, M., Nishiwaki, Y., Eguchi, K., & Ochiai, A. (2009). Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.Lung Cancer,64(1), 98–104. https: //doi.org/10.1016/j.lungcan.2008.07.014

[73]Li, F., Zeng, H., & Ying, K. (2011). The combination of stem cell markers CD133 and ABCG2 predicts relapse in stage I non-small cell lung carcinomas.Medical Oncology,28(4), 1458–1462. https: //doi.org/10.1007/s12032-010-9646-5

[74]Jelen, A., Zebrowska-Nawrocka, M., Lochowski, M., Szmajda-Krygier, D., & Balcerczak, E. (2024). ABCG2 gene expression in non-small cell lung cancer.Biomedicines,12(10), 2394. https: //doi.org/10.3390/biomedicines12102394

[75]Meng, X., Wang, G., Liu, P., Hou, J., Jin, Y., Yu, Y., Bai, J., Chen, F., Sun, W., & Fu, S. (2011). ATP-binding cassette B1 gene polymorphisms, mRNA expression and chemosensitivity to paclitaxel in non-small cell lung cancer cells.Respirology,16(8), 1228–1234. https: //doi.org/10.1111/j.1440-1843.2011.02050.x

[76]Yabuki, N., Sakata, K., Yamasaki, T., Terashima, H., Mio, T., Miyazaki, Y., Fujii, T., & Kitada, K. (2007). Gene amplification and expression in lung cancer cells with acquired paclitaxel resistance.Cancer Genetics and Cytogenetics,173(1), 1–9. https: //doi.org/10.1016/j.cancergencyto.2006.07.020

[77]Han, L., Wang, Y. F., Zhang, Y., Wang, N., Guo, X. J., Yang, J. K., Wang, K. P., Liu, S. N., Fan, Q. X., Li, K., Jiang, J. H., & Wang, Q. D. (2012). Increased expression and function of P-glycoprotein in peripheral blood CD56+ cells is associated with the chemoresistance of non-small-cell lung cancer.Cancer Chemotherapy and Pharmacology,70(3), 365–372. https: //doi.org/10.1007/s00280-012-1915-x

[78]Galetti, M., Petronini, P. G., Fumarola, C., Cretella, D., La Monica, S., Bonelli, M., Cavazzoni, A., Saccani, F., Caffarra, C., Andreoli, R., Mutti, A., Tiseo, M., Ardizzoni, A., & Alfieri, R. R. (2015). Effect of ABCG2/BCRP expression on efflux and uptake of gefitinib in NSCLC cell lines.PLOS ONE,10(11), e0141795. https: //doi.org/10.1371/journal.pone.0141795

[79]Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., Antipin, Y., Reva, B., Goldberg, A. P., Sander, C., & Schultz, N. (2012). The cBio Cancer Genomics Portal: An open platform for exploring multidimensional cancer genomics data.Cancer Discovery,2(5), 401–404. https: //doi.org/10.1158/2159-8290.CD-12-0095

[80]National Cancer Institute. (n.d.)(2026). About the program. The Cancer Genome Atlas (TCGA).Retrieved January 24, from https: //www.cancer.gov/ccg/research/genome-sequencing/tcga/history

[81]Muriithi, W., Macharia, L. W., Heming, C. P., Echevarria, J. L., Nyachieo, A., Filho, P. N., & Neto, V. M. (2020). ABC transporters and the hallmarks of cancer: Roles in cancer aggressiveness beyond multidrug resistance.Cancer Biology & Medicine,17(2), 253–269. https: //doi.org/10.20892/j.issn.2095-3941.2019.0284

[82]Dvorak, P., Pesta, M., & Soucek, P. (2017). ABC gene expression profiles have clinical importance and possibly form a new hallmark of cancer.Tumor Biology,39(5), 1010428317699800. https: //doi.org/10.1177/1010428317699800

[83]Parisi, G. F., Papale, M., Pecora, G., Rotolo, N., Manti, S., Russo, G., & Leonardi, S. (2023). Cystic fibrosis and cancer: Unraveling the complex role of CFTR gene in cancer susceptibility.Cancers,15(17), 4244. https: //doi.org/10.3390/cancers15174244

[84]Maráz, A., Furák, J., Pálföldi, R., Eller, J., Szántó, E., Kahán, Z., Thurzó, L., Molnár, J., Tiszlavicz, L., & Hideghéty, K. (2011). Roles of BCL-2 and MDR1 expression in the efficacy of paclitaxel-based lung cancer chemoradiation.Anticancer research,31(4), 1431–1436.

[85]Chen, Y., Zhou, H., Yang, S., & Su, D. (2021). Increased ABCC2 expression predicts cisplatin resistance in non-small cell lung cancer.Cell biochemistry and function,39(2), 277–286. https: //doi.org/10.1002/cbf.3577